Postprogression Survival of Patients with Metastatic Hormone-sensitive Prostate Cancer who Received Darolutamide or Placebo in Combination with Docetaxel and Androgen Deprivation Therapy: Post Hoc Analysis of the Phase 3 ARASENS Trial

Journal:
European Urology
Published:
DOI:
10.1016/j.eururo.2025.05.037
Affiliations:
10
Authors:
10
Go to article
Institutions Authors Share
Bayer Consumer Care AG, Switzerland
2.000000
 0.20
Hospital of the University of Montreal (CHUM), Canada
1.000000
 0.10
Jena University Hospital (UKJ), FSU, Germany
1.000000
 0.10
University Hospital Saint-Luc, Belgium
1.000000
 0.10
Bayer HealthCare, United States of America (USA)
1.000000
 0.10
Bayer Ireland, Ireland
1.000000
 0.10
Northwestern Medicine, United States of America (USA)
1.000000
 0.10
Massachusetts General Hospital (MGH), United States of America (USA)
1.000000
 0.10
Institute Gustave-Roussy (IGR), France
0.500000
 0.05
University of Paris-Saclay, France
0.500000
 0.05
Interested in Oncology and Carcinogenesis?